Governmental or Regulatory Activity
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal
House Speaker Plans Vote on Biosecure Act Amid Broader China Legislation Push
House Speaker, Biosecure Act, China Legislation, National Security, Biotech Companies
US Speaker Promises Vote on BIOSECURE Act to Halt Federal Contracts with Chinese Biotech Companies
BIOSECURE Act, House Speaker Mike Johnson, Chinese biotech companies, federal contracts, healthcare data, national security
Medicare Drug Price Negotiation Program Upheld in Court, Defeating Boehringer Ingelheim’s Challenge
Medicare, drug pricing, negotiation program, Boehringer Ingelheim, legal challenge, pharmaceutical industry, healthcare policy
Medicare Patients to Save on 64 Prescription Drugs with Prices Above Inflation Rate
Medicare, Prescription Drugs, Inflation Reduction Act, Price Rebates, Healthcare Costs
Johnson & Johnson to Appeal $150 Million Verdict in HIV Meds Off-Label Marketing Case
Johnson & Johnson, HIV Meds, Off-Label Marketing, Appeal, $150 Million Verdict
FDA Advisory Panel Rejects Lykos’ MDMA Treatment for PTSD Despite Promising Results
MDMA, PTSD, FDA, Lykos Therapeutics, Psychopharmacologic Drugs Advisory Committee, psychedelic therapy
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency
Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift